[1] |
Bedikian AY. Metastatic uveal melanoma therapy: current options[J]. Int Ophthalmol Clin,2006,46(1):151-166.
|
[2] |
Patel SP. Latest developments in the biology and management of uveal melanoma[J]. Curr Oncol Rep,2013,15(6):509-516.
|
[3] |
Field MG,Harbour JW. Recent developments in prognostic and predictive testing in uveal melanoma[J]. Curr Opin Ophthalmol, 2014,25(3):234-239.
|
[4] |
Munzenrider JE. Uveal melanomas. Conservation treatment[J]. Hematol Oncol Clin North Am,2001,15(2):389-402.
|
[5] |
Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15[J]. Arch Ophthalmol,2001,119(5):670-676.
|
[6] |
Gragoudas ES, Egan KM, Seddon JM, et al. Survival of patients with metastases from uveal melanoma[J]. Ophthalmology,1991, 98(3):383-389.
|
[7] |
Kath R, Hayungs J, Bornfeld N, et al. Prognosis and treatment of disseminated uveal melanoma[J]. Cancer,1993,72(7):2219-2223.
|
[8] |
Kaur J, Malik MA, Gulati R, et al. Genetic determinants of uveal melanoma[J]. Tumour Biol,2014,35(12):11711-11777.
|
[9] |
Shields CL, Ganguly A, Bianciotto CG, et al. Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens[J]. Ophthalmology,2011,118(2):396-401.
|
[10] |
Kilic E, Naus NC, van Gils W, et al. Concurrent loss of chromosome arm 1p and chromosome 3 predicts a decreased disease-free survival in uveal melanoma patients[J]. Invest Ophthalmol Vis Sci,2005,46(7):2253-2257.
|
[11] |
Sisley K, Rennie IG, Parsons MA, et al. Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis[J]. Genes Chromosomes Cancer,1997,19(1):22-28.
|
[12] |
Parrella P, Sidransky D,Merbs SL. Allelotype of posterior uveal melanoma: implications for a bifurcated tumor progression pathway[J]. Cancer Res,1999,59(13):3032-3037.
|
[13] |
Onken MD, Worley LA , Ehlers JP, et al. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death[J]. Cancer Res,2004,64(20):7205-7209.
|
[14] |
Gill HS, Char DH. Uveal melanoma prognostication: from lesion size and cell type to molecular class[J]. Can J Ophthalmol, 2012,47(3):246-253.
|
[15] |
Harbour JW. A prognostic test to predict the risk of metastasis in uveal melanoma based on a 15-gene expression profile[J]. Methods Mol Biol,2014,1102:427-440.
|
[16] |
Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma[J]. N Engl J Med,2010,363(23):2191-2199.
|
[17] |
Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi[J]. Nature,2009,457(7229):599-602.
|
[18] |
Xu X, Wei WB, Li B, et al. Oncogenic GNAQ and GNA11 Mutations in Uveal Melanoma in Chinese[J]. PLoS One,2014, 9(10):e109699.
|
[19] |
Chen X, Wu Q, Tan L, et al. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations[J]. Oncogene,2014,33(39):4724-4734.
|
[20] |
Yu FX, Luo J, Mo JS, et al. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP[J]. Cancer Cell, 2014,25(6):822-830.
|
[21] |
Feng X, Degese MS, Iglesias-Bartolome R, et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry[J]. Cancer Cell, 2014,25(6):831-845.
|
[22] |
Harbour JW, Onken MD, Roberson ED, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas[J]. Science,2010, 330(6009):1410-1413.
|
[23] |
Landreville S, Agapova OA, Matatall KA, et al. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma[J]. Clin Cancer Res,2012,18(2):408-416.
|
[24] |
Harbour JW, Roberson ED, Anbunathan H, et al. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma[J]. Nat Genet,2013,45(2):133-135.
|
[25] |
Martin M, Masshofer L, Temming P, et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3[J]. Nat Genet,2013,45(8):933-936.
|
[26] |
Zuidervaart W, van Nieuwpoort F, Stark M, et al. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS[J]. Br J Cancer,2005,92(11):2032-2038.
|
[27] |
Populo H, Soares P, Rocha AS, et al. Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma[J]. Melanoma Res,2010,20(2):107-117.
|
[28] |
Abdel-Rahman MH, Yang Y, Zhou XP, et al. High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma[J]. J Clin Oncol, 2006,24(2):288-295.
|
[29] |
Economou MA, All-Ericsson C, Bykov V, et al. Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications[J]. Invest Ophthalmol Vis Sci,2005,46(12):4372-4375.
|
[30] |
Mallikarjuna K, Pushparaj V, Biswas J, et al. Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: an immunohistochemical study[J]. Curr Eye Res,2007,32(3):281-290.
|
[31] |
Gardner FP, Serie DJ, Salomao DR, et al. c-MET expression in primary and liver metastases in uveal melanoma[J]. Melanoma Res,2014,24(6):617-620.
|
[32] |
Economou MA, All-Ericsson C, Bykov V, et al. Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications[J]. Acta Ophthalmol,2008,86:20-25.
|
[33] |
All-Ericsson C, Girnita L, Seregard S, et al. Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target[J]. Invest Ophthalmol Vis Sci,2002,43(1):1-8.
|
[34] |
Yoshida M, Selvan S, McCue PA, et al. Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth[J]. Pigment Cell Melanoma Res,2014,27(2):297-308.
|
[35] |
Anonymous. Selumetinib shows promise in metastatic uveal melanoma[J]. Cancer Discov,2013,3(7):OF8.
|